NCT07260942 Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
| NCT ID | NCT07260942 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Systemic Lupus Erythematosus |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-04-21 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-04-21 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years; * diagnosis of systemic lupus erythematosus; * being affiliated to health insurance, willing to participate and to sign informed consent; * control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease. Exclusion Criteria: * pregnant or breastfeeding women; * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Contact & Investigator
Christophe RICHEZ, Prof
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT07260942 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Systemic Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07260942 currently recruiting?
Yes, NCT07260942 is actively recruiting participants. Contact the research team at christophe.richez@chu-bordeaux.fr for enrollment information.
Where is the NCT07260942 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT07260942 clinical trial?
NCT07260942 is sponsored by University Hospital, Bordeaux. The principal investigator is Christophe RICHEZ, Prof at University Hospital, Bordeaux. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.